Clear Note Health announced it raised $21.8 Million in an initial filing from an offering of $60.5 Million

Company

Location

About

ClearNote Health is a privately held company dedicated to improving early detection and monitoring for some of the deadliest forms of cancer. Developed by scientists in the Stephen Quake laboratory at Stanford University, the company’s patented core Virtuoso® epigenomics platform utilizes advances in artificial intelligence and bioinformatics. Their noninvasive Avantect® tests are designed to identify cancers in high-risk patient populations far earlier than conventional approaches. ClearNote Health aims to enhance patient outcomes through innovative cancer detection technologies.